How Novo Nordisk misread the US market for its weight loss sensation

Novo Nordisk executives reportedly disregarded internal warnings about insufficient preparation for Wegovy's launch, leading to supply shortages and high patient out-of-pocket costs due to inadequate insurance coverage. This strategic misstep, driven by conservative internal forecasts and a rushed market entry, enabled Eli Lilly's Zepbound to quickly surpass Wegovy in new prescriptions, challenging Novo's dominance in the lucrative weight-loss market. The company's high pricing and reluctance to offer rebates further compounded these issues, contributing to recent leadership changes and raising concerns about Novo's competitive agility against Lilly's more aggressive approach.

Analysis

Novo Nordisk's execution of its Wegovy launch was undermined by significant strategic miscalculations, allowing rival Eli Lilly to capture critical market momentum. According to former employees, Novo's leadership ignored internal warnings about inadequate supply and insurance coverage, proceeding with a launch based on severely underestimated demand forecasts. Despite internal research and market feedback suggesting explosive growth, the company's official projection was to merely double 2019 obesity sales by 2025, a target that was vastly surpassed as sales reached 65.1 billion Danish crowns in 2024. This forecasting failure led to persistent supply shortages and high out-of-pocket costs for patients, as Wegovy was priced at over $1,300 per month without sufficient payer rebates. In contrast, Eli Lilly entered the market with Zepbound at a lower price point ($1,080), with ample supply and more aggressive commercial strategies, resulting in its new weekly prescriptions overtaking Wegovy's. The fallout at Novo includes a leadership shake-up, including the ouster of its CEO, and has fostered a perception among investors and analysts of the company being inflexible and conservative compared to a more agile and strategic Eli Lilly.

Key Decisions for Investors

• Investors in Novo Nordisk should closely scrutinize the new leadership's ability to correct the strategic missteps in supply chain management and competitive pricing, as the company's market dominance is now under significant threat from Eli Lilly.
• The evidence of Eli Lilly's superior execution and aggressive market entry strategy reinforces a bullish case for LLY, suggesting it is well-positioned to continue capturing market share in the lucrative obesity drug sector.
• Monitor key leading indicators such as weekly prescription volumes for Zepbound versus Wegovy and any shifts in Novo's payer contracts, as these will be critical in assessing whether Novo can stem its market share erosion.
• Consider that the issues highlighted—poor forecasting, pricing inflexibility, and management turnover—introduce significant execution risk for Novo Nordisk, which may not be fully priced into the stock despite its strong historical performance.